Search - tctmd.com

Displaying 261 - 280 of 764

Sort: Relevancy | Date

News Daily News

Goodbye BMS? New DAPT Analysis Shows Less Stent Thrombosis With DES

Yael L. Maxwell

October 26, 2015

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Cindy L. Grines, Upendra Kaul

October 14, 2015

Presentation TCT 2015

TWENTE: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Five-Year Outcomes

Presenter: Bernard J. Gersh, Thomas F. Luscher, Clemens von Birgelen

October 14, 2015

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Upendra Kaul

October 14, 2015

News Conference News TCT 2015

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Industry News

Randomized Trial Of Diabetic Patients In India Finds Paclitaxel-Eluting Stents Failed To Meet Non-Inferiority Compared To Everolimus-Eluting Stents

October 14, 2015

Presentation TCT 2015

TCT 65: Two-Year Outcomes in Real-World Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus US Postapproval Study (PE-Plus PAS)

Presenter: Sigmund Silber, Philip M. Urban, David E. Kandzari

October 13, 2015

Presentation TCT 2015

TCT 6: Five-Year Optical Coherence Tomography of Patients With ST-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents (the RE-EXAMINATION Study)

Presenter: Eric Boersma, Richard Smalling, Josep Gomez Lara

October 13, 2015

Presentation TCT 2015

TCT 48: Early Vascular Responses to Everolimus-Eluting Cobalt-Chromium Stent for the Treatment of Stable Coronary Artery Disease The Results of MECHANISM Elective 1-Month OCT Follow-up Cohort

Presenter: Stephan Achenbach, Marc D. Feldman, Toshiro Shinke

October 13, 2015

Presentation TCT 2015

TCT 12: Impact of Overlap on Long-term Clinical Outcomes in Patients Undergoing Everolimus-Eluting Bioresorbable Vascular Scaffolds Implantation in Routine Clinical Practice Insights From the European Multicenter GHOST-EU Registry

Presenter: Stephen G. Ellis, Lorenz Raber, Luis Ortega-Paz

October 13, 2015

Presentation TCT 2015

TCT 11: Five-year Follow-up of the First-in-Man Use of a Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: A Serial Multi-Imaging Modality Study

Presenter: Stephen G. Ellis, Lorenz Raber, Patrick W. Serruys

October 13, 2015

News Conference News TCT 2015

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

October 13, 2015

Presentation TCT 2015

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease - Two-Year Outcomes

Presenter: Ioanna Kosmidou, Bernard R. Chevalier

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

CENTURY II: A Prospective Randomized Trial of a Bioabsorbable-Polymer Biolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Two-Year Outcomes

Presenter: Spencer B. King III, Jagat Narula, Shigeru Saito

October 12, 2015

Presentation TCT 2015

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

Presenter: Spencer B. King III, Jagat Narula, James B. Hermiller Jr

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Run-Lin Gao, Gregg W. Stone, Ron Waksman, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Gregg W. Stone, Ron Waksman, Dean J. Kereiakes

October 12, 2015

Advertisement

Goodbye BMS? New DAPT Analysis Shows Less Stent Thrombosis With DES

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

TWENTE: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Five-Year Outcomes

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Randomized Trial Of Diabetic Patients In India Finds Paclitaxel-Eluting Stents Failed To Meet Non-Inferiority Compared To Everolimus-Eluting Stents

TCT 65: Two-Year Outcomes in Real-World Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus US Postapproval Study (PE-Plus PAS)

TCT 6: Five-Year Optical Coherence Tomography of Patients With ST-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents (the RE-EXAMINATION Study)

TCT 48: Early Vascular Responses to Everolimus-Eluting Cobalt-Chromium Stent for the Treatment of Stable Coronary Artery Disease The Results of MECHANISM Elective 1-Month OCT Follow-up Cohort

TCT 12: Impact of Overlap on Long-term Clinical Outcomes in Patients Undergoing Everolimus-Eluting Bioresorbable Vascular Scaffolds Implantation in Routine Clinical Practice Insights From the European Multicenter GHOST-EU Registry

TCT 11: Five-year Follow-up of the First-in-Man Use of a Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: A Serial Multi-Imaging Modality Study

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease - Two-Year Outcomes

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

CENTURY II: A Prospective Randomized Trial of a Bioabsorbable-Polymer Biolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Two-Year Outcomes

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content